Vitruvian Therapeutics

Vitruvian Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation gene therapies for inherited retinal diseases. The company was co-founded by Dr. Jean Bennett and Dr. Albert Maguire, the pioneers behind the first FDA-approved gene therapy, Luxturna. Vitruvian's lead program focuses on treating Stargardt disease, a leading cause of inherited macular degeneration, by delivering a functional ABCA4 gene using a specialized adeno-associated virus (AAV) vector. The company leverages its founders' deep expertise in ocular gene therapy to address the challenges of large-gene delivery and precise retinal targeting. Headquartered in Philadelphia, Vitruvian aims to restore visual function and prevent blindness in patients with rare genetic disorders.